scholarly journals The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations

2021 ◽  
pp. 1-14
Author(s):  
Steve Duff ◽  
Francesca Bargiacchi ◽  
Chelsea Norregaard ◽  
Melanie Brener ◽  
Erin Sullivan
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Health Plan ◽  
Cell Lung Cancer ◽  
Budget Impact ◽  
Small Cell ◽  
Small Cell Lung

A contemporary review of rearranged during transfection-selective inhibitors

2021 ◽  
pp. 107815522110405
Author(s):  
Angel W Liu ◽  
Connie Liang ◽  
Chung-Shien Lee
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Objective Response ◽  
Small Cell ◽  
Suppressive Therapy ◽  
Selective Inhibitors ◽  
Small Cell Lung ◽  
Pivotal Phase

Objective Rearranged during transfection genes are present in 1−2% of patients who have non-small cell lung cancer and 10−30% of patients with papillary thyroid cancer. The objective of this article is to review the current rearranged during transfection inhibitors indicated for patients with rearranged during transfection-mutated cancers and their future directions. Data sources: The pivotal phase I/II studies for selpercatinib and pralsetinib were evaluated. Current studies on rearranged during transfection inhibitors were searched on ClinicalTrials.gov using the key word “RET.” Data summary: Selpercatinib and pralsetinib were the first two U.S. Food and Drug Administration-approved rearranged during transfection-selective inhibitors for advanced or metastatic rearranged during transfection fusion-positive non-small cell lung cancer, rearranged during transfection-mutant medullary thyroid cancer, and rearranged during transfection fusion-positive thyroid cancer. Both agents showed promising efficacy with objective response rate ranging from 60% to 73% in all aforementioned rearranged during transfection-mutated cancers. Additionally, benefits were seen even in patients with intracranial metastasis at baseline. Both showed favorable safety profiles. Some common class adverse events included elevated liver function tests and hypertension. Hematologic side effects such as anemia and neutropenia were more common with pralsetinib. Selpercatinib had interactions with acid suppressive therapy and specific instructions when used concomitantly. Conclusions While the rearranged during transfection inhibitors are generally well-tolerated, each agent possesses slightly different efficacy, side-effect profile, and drug−drug interactions.

scholarly journals PCN124 BUDGET IMPACT ANALYSIS OF IMMUNOTHERAPY AS SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AT MEXICO´S NATIONAL INSTITUTE OF CANCER

2019 ◽  
Vol 22 ◽  
pp. S459-S460
Author(s):  
F. Barrón-Barrón ◽  
A.A. Meneses-García ◽  
L.M. Rivera ◽  
J. de la Garza-Salazar ◽  
A.F. Cardona ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Impact Analysis ◽  
Budget Impact ◽  
Small Cell ◽  
Budget Impact Analysis ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung

Two Cases of Non-Small Cell Lung Cancer Masquerading as Metastatic Papillary Thyroid Cancer

2012 ◽  
Vol 5 (2) ◽  
pp. 157
Author(s):  
Ju Hee Lee ◽  
Se-Hoon Lee ◽  
Hye Sook Min ◽  
Ji-hoon Kim ◽  
Do Joon Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Papillary Thyroid Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Papillary Thyroid ◽  
Small Cell Lung

scholarly journals Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non–Small Cell Lung Cancer

2018 ◽  
Vol 21 (11) ◽  
pp. 1278-1285 ◽  
Author(s):  
Tiffany M. Yu ◽  
Carl Morrison ◽  
Edward J. Gold ◽  
Alison Tradonsky ◽  
Renée J.G. Arnold
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Budget Impact ◽  
Small Cell ◽  
Next Generation ◽  
Small Cell Lung ◽  
Molecular Assessment ◽  
Generation Sequencing

Evaluation of molecular testing patterns in metastatic non-small cell lung cancer at a large U.S. health plan.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e19075-e19075
Author(s):  
Elizabeth A. MacLean ◽  
Anthony M. Louder ◽  
Kimberly R. Saverno ◽  
Gregory Smith ◽  
Jack Mardekian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Health Plan ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Molecular Testing ◽  
Small Cell Lung ◽  
Testing Patterns
Sign in / Sign up

Export Citation Format

Share Document